



August 2008

# I/LA29-A

## Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Approved Guideline

This guideline describes criteria for optimizing methods that utilize flow cytometry and other conventional and multiplex platforms.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in clinical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

## Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: 610.688.0100  
F: 610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

consensus process. However, because of its usefulness to segments of the health care community, it is available for its informational content.

ISBN 1-56238-676-X  
ISSN 0273-3099

I/LA29-A  
Vol. 28 No. 24  
Replaces I/LA29-P  
Vol. 27 No. 28

---

## Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Approved Guideline

Volume 28 Number 24

Daniel J. Cook, PhD  
Ivan Balazs, PhD  
Lee Ann Baxter-Lowe, PhD, D(ABHI)  
Deborah O. Crowe, PhD, D(ABHI)  
Gerald E. Marti, MD, PhD  
Cathi Murphey, CHS, DLM(ASCP)  
Karen A. Nelson, PhD, D(ABHI)  
Robert F. Vogt, Jr., PhD  
William W. Ward, PhD, D(ABHI)

### Abstract

The current and emerging technologies for detecting and characterizing human leukocyte antigen (HLA) alloantibodies provide powerful tools for predicting the risk of immunological response to a transplant. Clinical and Laboratory Standards Institute document I/LA29-A—*Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Approved Guideline* describes criteria for optimizing methods that utilize flow cytometry and other conventional and multiplex platforms. The intended audience includes solid organ and stem cell transplant laboratories, manufacturers of systems for histocompatibility testing, and organizations that manage organ sharing.

Clinical and Laboratory Standards Institute (CLSI). *Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Approved Guideline*. CLSI document I/LA29-A (ISBN 1-56238-676-X). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2008.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



Copyright ©2008 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Approved Guideline*. CLSI document I/LA29-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.

### **Proposed Guideline**

December 2007

### **Approved Guideline**

August 2008

ISBN 1-56238-676-X  
ISSN 0273-3099

## Committee Membership

### Area Committee on Immunology and Ligand Assay

**Dorothy J. Ball, PhD**  
**Chairholder**  
**Abbott**  
**Irving, Texas**

**Robin G. Lorenz, MD, PhD**  
**Vice-Chairholder**  
**University of Alabama at**  
**Birmingham**  
**Birmingham, Alabama**

Joan H. Howanitz, MD  
SUNY Brooklyn  
Brooklyn, New York

Marilyn M. Lightfoote, MD, PhD  
FDA Ctr. for Devices/Rad. Health  
Silver Spring, Maryland

Tom H. Stahlberg  
Wallac Oy  
Turku, Finland

Robert F. Vogt, Jr., PhD  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia

Ronald J. Whitley, PhD  
University of Kentucky Med. Ctr.  
Lexington, Kentucky

#### Advisors

W. Harry Hannon, PhD  
Centers for Disease Control and  
Prevention  
Atlanta, Georgia

Gerald E. Marti, MD, PhD  
FDA Ctr. for Biologics  
Evaluation/Research  
Bethesda, Maryland

Per N. J. Matsson, PhD  
Pharmacia and Upjohn Diagnostics  
Uppsala, Sweden

Robert M. Nakamura, MD  
Scripps Clinic & Research  
Foundation  
La Jolla, California

Thomas A. O'Brien, PhD  
Ortho Biotech Products LP  
Bridgewater, New Jersey

Jelili Ojodu, MPH  
Association of Public Health  
Laboratories  
Silver Spring, Maryland

Robert F. Ritchie, MD  
Foundation for Blood Research  
Scarborough, Maine

Donald R. Tourville, PhD  
Zeus Scientific, Inc.  
Raritan, New Jersey

Daniel Tripodi, PhD  
The Sage Group  
Bridgewater, New Jersey

Robert W. Veltri, PhD  
Johns Hopkins Hospital  
Baltimore, Maryland

Philip R. Wyatt, MD, PhD  
North York General Hospital  
North York, Ontario, Canada

### Subcommittee on HLA Detection by Flow Cytometry

**Daniel J. Cook, PhD**  
**Chairholder**  
**One Lambda Inc.**  
**Canoga Park, California**

Ivan Balazs, PhD  
Tepnel Lifecodes Corporation  
Stamford, Connecticut

Lee Ann Baxter-Lowe, PhD,  
D(ABHI)  
University of California, San  
Francisco  
San Francisco, California

Deborah O. Crowe, PhD, D(ABHI)  
DCI Laboratory  
Nashville, Tennessee

Gerald E. Marti, MD, PhD  
FDA Ctr. for Biologics  
Evaluation/Research  
Bethesda, Maryland

Cathi Murphey, CHS, DLM(ASCP)  
Southwest Immunodiagnosics, Inc.  
San Antonio, Texas

Karen A. Nelson, PhD, D(ABHI)  
Puget Sound Blood Center  
Seattle, Washington

William W. Ward, PhD, D(ABHI)  
MedStar Research Institute  
Hyattsville, Maryland

Ralf Wassmuth, MD, PhD  
DKMS Life Science GmbH  
Dresden, Germany

#### Advisors

Bruce H. Davis, MD  
Eastern Maine Medical Center  
Bangor, Maine

John A. Gerlach, PhD, D(ABHI)  
Michigan State University  
East Lansing, Michigan

#### Staff

Clinical and Laboratory Standards  
Institute  
Wayne, Pennsylvania

Lois M. Schmidt, DA  
*Vice President, Standards  
Development and Marketing*

Ron Quicho, BS  
*Staff Liaison*

Melissa A. Lewis  
*Editor*



**Contents**

Abstract.....i

Committee Membership..... iii

Foreword..... vii

1 Scope.....1

2 Standard Precautions.....1

3 Terminology.....1

    3.1 A Note on Terminology .....1

    3.2 Definitions .....2

    3.3 Abbreviations/Acronyms .....6

4 Biosafety .....7

    4.1 Specimen Collection .....7

    4.2 Safety Attire.....7

    4.3 Biological Safety Cabinets.....8

    4.4 Specimen Containers .....8

    4.5 Centrifugation .....8

    4.6 Pipetting .....8

    4.7 Sharp Devices .....8

    4.8 Blood Spills.....8

    4.9 Waste Disposal and Specimen Inactivation.....8

    4.10 Unfixed Specimens .....8

    4.11 Equipment Disinfection .....9

5 Solid Phase Methods.....9

    5.1 Overview.....9

    5.2 Specimens .....10

    5.3 Attachment of Antigens to the Matrix .....11

    5.4 Limitations for All Solid-Phase Assays .....11

    5.5 Enzyme-Linked Immunosorbent Assay.....14

    5.6 Microsphere-Based Multiplexing Flow System .....15

    5.7 Microchips .....16

6 Human Leukocyte Antigen Antibody Screening Methodologies .....17

    6.1 Introduction.....17

    6.2 Data Analysis and Interpretation of Solid Phase Human Leukocyte Antigen  
Antibody Screening Assays .....17

    6.3 Quality Control for Solid Phase Antibody Screening Assays.....20

    6.4 Limitations of Solid Phase Antibody Screening Assays.....22

7 Identification Using Multiantigen Panels .....22

    7.1 Introduction/Overview .....22

    7.2 Data Analysis and Interpretation of Antibody Specificity .....23

    7.3 Limitations of Multiantigen Methods and Technical Considerations.....29

8 Single Antigen Approaches .....30

    8.1 Introduction/Overview .....30

**Contents (Continued)**

8.2 Data Analysis and Interpretation of Single Antigen (High Definition) Assays.....31

8.3 Quality Control for Solid Phase Single Antigen Assays for Human Leukocyte  
Antigen Antibody Specificity .....33

8.4 Limitations of Solid Phase Single Antigen Assays for Human Leukocyte Antigen  
Antibody Specificity .....34

9 Flow Cytometric Crossmatch .....35

9.1 Background.....35

9.2 General Methodological Choices.....35

9.3 Basic Procedure .....35

9.4 Interpretation of Results.....36

9.5 Limitations/Problems.....36

10 Clinical Relevance of Antibodies Identified Using Solid Phase Assays .....37

10.1 Background.....37

10.2 Clinical Relevance .....37

10.3 Advantages of Solid Phase Assays .....37

10.4 Limitations of Solid Phase Assays.....38

10.5 Uses for Solid Phase Assays.....38

10.6 Best Practices for Use of Solid Phase Assays.....39

References.....40

Appendix. Assessment of Delayed Shipping and Processing on Human Leukocyte Antigen Antibody  
Results .....42

Summary of Comments and Subcommittee Responses.....44

The Quality Management System Approach .....46

Related CLSI Reference Materials .....47



## Foreword

The current technologies for detecting and characterizing human leukocyte antigen (HLA) alloantibodies in patients awaiting transplants are among the most significant advances in the field of clinical histocompatibility. The benefit of these advances is clear and measurable. In the early days of organ transplantation, hyperacute rejection (where the graft is lost immediately in the operating room) was not uncommon. A transplant surgeon training today may never experience such a devastating event in his or her career. The impact on transplanting sensitized patients is even greater. In contrast to the historically poor prognosis for organ survival, it is now normal for sensitized patients—in particular, those undergoing retransplantation—to have graft survival rates the same as primary transplant recipients.

Current technologies allow a donor organ to be matched with a sensitized patient by predicting the crossmatch using detailed specificity analysis of the patient's HLA antibodies. However, even with the predictive value of HLA antibody profiling, flow cytometric crossmatching remains an important procedure in the histocompatibility laboratory. The ability to gate out dead cells on the flow cytometer using light scatter often allows interpretable results to be obtained even when lymphocyte viability is low.

Appropriate utilization of these powerful tools allows clinical transplant centers to transplant the most difficult patients and provide them with excellent chances for a successful outcome. By standardizing methods, quality control, and clinical interpretations, transplant centers can more readily identify optimal donor-recipient pairs and encourage organ sharing. The optimal use of precious donor organs is the overarching goal of this consensus guideline.

## Key Words

Alloantibodies, avidity, crossmatch, cryptic epitope, donor-specific antibody (DSA), flow crossmatch/flow cytometric crossmatch, HLA, multiantigen



## **Detection of HLA-Specific Alloantibody by Flow Cytometry and Solid Phase Assays; Approved Guideline**

### **1 Scope**

This guideline describes criteria for optimizing flow cytometry crossmatching and the detection of human leukocyte antigen (HLA) alloantibody by solid-phase methods in conventional and multiplex platforms. Specific areas include technical consideration for instrument setup and staining procedures, screening methods, single-antigen and multiantigen approaches, reporting formats, clinical interpretation, and multicenter quality assurance. The guideline does not address cytotoxicity assays or standard methods for lymphocyte immunophenotyping, which are covered in CLSI document H42.<sup>1</sup> The intended users of this guideline are: 1) laboratories conducting tests of histocompatibility for solid organ and stem cell transplants; 2) manufacturers of reagents and systems for conducting such tests; and 3) organizations that promulgate organ sharing between transplant centers.

### **2 Standard Precautions**

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention.<sup>2</sup> For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to CLSI document M29.<sup>3</sup>

### **3 Terminology**

#### **3.1 A Note on Terminology**

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all challenges to harmonization. In light of this, CLSI recognizes that harmonization of terms facilitates the global application of standards and deserves immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

In order to align the usage of terminology in this document with that of ISO, I/LA29-A describes *reproducibility* as the closeness of agreement of results of measurements under changed conditions.

Users of I/LA29-A should understand, however, that the fundamental meanings of the terms are identical in many cases, and to facilitate understanding, terms are defined in Section 3.2 of this guideline.

All terms and definitions will be reviewed again for consistency with international use, and revised appropriately during the next scheduled revision of this document.